Literature DB >> 10676626

Expression of a highly conserved protein, p27BBP, during the progression of human colorectal cancer.

F Sanvito1, F Vivoli, S Gambini, G Santambrogio, M Catena, E Viale, F Veglia, A Donadini, S Biffo, P C Marchisio.   

Abstract

The highly conserved protein p27BBP is a cytoplasmic interactor of integrin beta4 expressed in epithelia. p27BBP is found in two pools: one nuclear pool enriched in the perinucleolar region, and one cytoplasmic pool. Deletion of p27BBP in yeast is lethal as a result of loss of the ribosomal 60S subunit. The aim of this study was to investigate the distribution of p27BBP in gut epithelium and its behavior during progression of human colorectal carcinomas. Results indicated that p27BBP is high in rapidly cycling cells and decreased in villous cells committed to apoptotic cell death. In dysplastic adenomas and carcinomas, p27BBP displayed a large increase of its nucleolar component that was superimposable to argyrophylic nucleolar organizing region-associated proteins and was associated with the nuclear matrix. Western blotting confirmed increased p27BBP in dysplastic adenomas and in carcinomas. In particular, p27BBP increased progressively from adenomas to carcinomas and, in the latter, was related to the tumor stage. The overexpression of p27BBP corresponded to mRNA up-regulation in carcinomas, supporting the idea of transcriptional or post-transcriptional regulation of its expression. Results suggested that p27BBP alterations are an early event in the transition from benign to malignant colorectal phenotypes and provide a novel tool in surgical pathology.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10676626

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

Review 1.  Translational control in cancer.

Authors:  Deborah Silvera; Silvia C Formenti; Robert J Schneider
Journal:  Nat Rev Cancer       Date:  2010-04       Impact factor: 60.716

Review 2.  Translational Control in Cancer.

Authors:  Nathaniel Robichaud; Nahum Sonenberg; Davide Ruggero; Robert J Schneider
Journal:  Cold Spring Harb Perspect Biol       Date:  2019-07-01       Impact factor: 10.005

Review 3.  Translational control in cancer etiology.

Authors:  Davide Ruggero
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-02-01       Impact factor: 10.005

Review 4.  The cancerous translation apparatus.

Authors:  Craig R Stumpf; Davide Ruggero
Journal:  Curr Opin Genet Dev       Date:  2011-05-03       Impact factor: 5.578

5.  Roles of HDAC2, eIF5, and eIF6 in Lung Cancer Tumorigenesis.

Authors:  Shao-Xin Cai; Wen-Shu Chen; Wei Zeng; Xue-Fei Cheng; Meng-Bo Lin; Jin-Si Wang
Journal:  Curr Med Sci       Date:  2021-08-17

6.  Eukaryotic initiation factor 6 is rate-limiting in translation, growth and transformation.

Authors:  Valentina Gandin; Annarita Miluzio; Anna Maria Barbieri; Anne Beugnet; Hiroaki Kiyokawa; Pier Carlo Marchisio; Stefano Biffo
Journal:  Nature       Date:  2008-09-10       Impact factor: 49.962

Review 7.  Eukaryotic initiation factor 6 mediates a continuum between 60S ribosome biogenesis and translation.

Authors:  Annarita Miluzio; Anne Beugnet; Viviana Volta; Stefano Biffo
Journal:  EMBO Rep       Date:  2009-04-17       Impact factor: 8.807

8.  The biological roles of ITGB4BP and its potential effect on fibrosis.

Authors:  Jianglin Tan; Gaoxing Luo; Jun Wu
Journal:  Int J Burns Trauma       Date:  2011-09-02

9.  Functional analysis of a novel glioma antigen, EFTUD1.

Authors:  Katsuya Saito; Yukihiko Iizuka; Shigeki Ohta; Satoshi Takahashi; Kenta Nakamura; Hideyuki Saya; Kazunari Yoshida; Yutaka Kawakami; Masahiro Toda
Journal:  Neuro Oncol       Date:  2014-07-11       Impact factor: 12.300

10.  Revising the Role of Integrin Subunit β4 Expression in Colon Cancer Progression and Survival.

Authors:  Eva Rademaker; Esther Bastiaannet; Jan Oosting; Neeltje G Dekker-Ensink; Peter J K Kuppen; Noel F C C de Miranda; Gerrit J Liefers
Journal:  J Gastrointest Cancer       Date:  2022-02-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.